Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout

Eli Lilly made a push in blood cancer at this year’s European Hematology Association presenting data for Jaypirca as well as its first-ever clinical trial results in myelofibrosis. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act…

Source: Endpoints News